Icosavax (NASDAQ:ICVX) Earns Buy Rating from Analysts at Guggenheim

Guggenheim started coverage on shares of Icosavax (NASDAQ:ICVX) in a research report report published on Friday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.

A number of other analysts have also recently commented on ICVX. William Blair reaffirmed an outperform rating on shares of Icosavax in a report on Wednesday, November 15th. Oppenheimer reissued an outperform rating and issued a $25.00 price objective on shares of Icosavax in a research note on Monday, October 2nd.

Icosavax Trading Down 4.4 %

Shares of ICVX stock opened at $10.75 on Friday. Icosavax has a 12 month low of $2.61 and a 12 month high of $16.45. The stock has a market cap of $538.47 million, a P/E ratio of -4.84 and a beta of 0.45. The company has a 50 day simple moving average of $7.35 and a two-hundred day simple moving average of $8.28.

Institutional Trading of Icosavax

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new stake in shares of Icosavax in the third quarter worth $199,000. Northern Trust Corp boosted its position in shares of Icosavax by 11.8% during the third quarter. Northern Trust Corp now owns 271,609 shares of the company’s stock worth $2,105,000 after acquiring an additional 28,686 shares during the last quarter. Federated Hermes Inc. bought a new position in shares of Icosavax during the third quarter worth $29,000. UBS Group AG boosted its position in shares of Icosavax by 97.6% during the third quarter. UBS Group AG now owns 14,544 shares of the company’s stock worth $113,000 after acquiring an additional 7,183 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Icosavax by 3,589.5% during the third quarter. Barclays PLC now owns 202,182 shares of the company’s stock worth $1,567,000 after acquiring an additional 196,702 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

About Icosavax

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.